Form 4: Beam Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director Mark Fishman acquired 23,114 stock options in Beam Therapeutics Inc. on June 5, 2024.
Summary
- On June 5, 2024, Mark Fishman, a director of Beam Therapeutics Inc., acquired 23,114 stock options.
- The exercise price of these options is $24.49.
- The options vest in full on the earlier of the first anniversary of the grant date or immediately prior to the date of the next year's annual meeting of stockholders, contingent upon continued service to the board.
- The options expire on June 5, 2034.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock option acquisition by a director, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure related to insider transactions, common in publicly traded companies. It provides transparency into the actions of company directors.
Stakeholder Impact
- The acquisition of stock options by a director can be seen as a positive sign by shareholders, indicating confidence in the company's future performance.
Key Dates
| Date | Description |
|---|---|
| 06/05/2024 | Date of stock option acquisition |
| 06/05/2024 | Stock option grant date |
| 06/05/2025 | Earliest possible vesting date for the stock options |
| 06/05/2034 | Expiration date of the stock options |
| 06/07/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.